LTR Pharma Limited
LTPLF
$0.27
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 146.80K | 151.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | 16.10K | 16.10K | -- |
| Total Revenue | 146.80K | 151.00K | 16.10K | 16.10K | -- |
| Cost of Revenue | 270.50K | 278.10K | -- | -- | 411.10K |
| Gross Profit | -123.60K | -127.10K | 16.10K | 16.10K | -411.10K |
| SG&A Expenses | 586.10K | 602.60K | 604.30K | 603.10K | 401.20K |
| Depreciation & Amortization | 300.00 | 300.00 | -- | -- | -- |
| Other Operating Expenses | 69.50K | 71.40K | 124.40K | 124.10K | 13.10K |
| Total Operating Expenses | 926.30K | 952.50K | 1.47M | 1.47M | 825.40K |
| Operating Income | -779.50K | -801.50K | -1.45M | -1.45M | -825.40K |
| Income Before Tax | -783.60K | -805.70K | -1.46M | -1.45M | -826.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -783.60K | -805.70K | -1.46M | -1.45M | -826.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -783.60K | -805.70K | -1.46M | -1.45M | -826.90K |
| EBIT | -779.50K | -801.50K | -1.45M | -1.45M | -825.40K |
| EBITDA | -779.10K | -801.10K | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 153.19M | 153.19M | 139.30M | 139.30M | 139.43M |
| Average Diluted Shares Outstanding | 153.19M | 153.19M | 139.30M | 139.30M | 139.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |